Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas
Isocitrate dehydrogenase (IDH) mutation is a valuable prognostic marker and a tool for decision-making for glioma treatment. An algorithm for IDH mutation screening was recently proposed—it consists of a two-step process of an initial search for the most common IDH1-R132H mutation using immunohistochemistry (IHC)-based assay, followed by DNA-based analysis of IHC-negative or -equivocal cases. Here, we report that immunohistochemistry using two mutation-specific anti-IDH monoclonal antibodies (mAbs)—an IDH1-R132H-specific mAb (clone HMab-1) and a multi-specific mAb (clone MsMab-1)—is easy and reliable for IDH mutation screening. We investigated the IDH status of 54 grade III gliomas. For the first screening, we used HMab-1 IHC and for the second, (of HMab-1-negative cases) we used MsMab-1 IHC. The double IHC screening results were confirmed using sequence analysis (100 % specificity and 100 % sensitivity). Thirty of 54 cases (55.6 %) had IDH mutations and the remaining 24 were of the IDH wild type; moreover, the screening results predicted grade III glioma prognosis. IDH sequencing procedures are popular but inconsistent across laboratories. By contrast, double IHC screening using HMab-1 and MsMab-1 is very reliable for detecting IDH1/2 mutations and can predict survival in grade III glioma patients.
KeywordsGlioma IDH Immunohistochemistry Monoclonal antibody Mutation
We thank Yoshiko Tsukada, Makiko Miyakawa, Takuro Nakamura, Noriko Saidoh, and Kanae Yoshida for their excellent technical assistance. This work was supported in part by Grants-in-Aid for Scientific Research (to S.T., No. 24390339; to Y.K., No. 25462242) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan; by the Platform for Drug Discovery, Informatics, and Structural Life Science from MEXT, Japan (to Y.K.); by the Basic Science and Platform Technology Program for Innovative Biological Medicine from MEXT, Japan (to Y.K.); by the Regional Innovation Strategy Support Program from MEXT, Japan (to Y.K.); by a Health Labour Sciences Research Grant from the Ministry of Health, Labour, and Welfare of Japan (to Y.K.); and by the Japan Brain Foundation (to S.T.) and the Japanese Foundation for Multidisciplinary Treatment of Cancer (to S.T.).
Conflict of interest
The authors declare no conflicts of interest.
- 5.Arita H, Narita Y, Matsushita Y et al (2014) Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol Apr 19. [Epub ahead of print] (PMID:24748374)Google Scholar
- 9.Kato Y (2014) Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol in press 2014 Oct 17. [Epub ahead of print]Google Scholar
- 14.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (2014) Central nervous system cancers, vol 1. Available via http://www.nccn.org. Accessed 14 Mar 2014
- 19.van den Bent MJ, Dubbink HJ, Marie Y et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597–1604PubMedCrossRefGoogle Scholar